Tags » GlaxoSmithKline

Testing Begins On Ebola Vaccine Developed By Local Drug Company

By Pat Loeb

PHILADELPHIA (CBS) – Human trials start this week on an Ebola vaccine developed by local pharmaceutical giant GlaxoSmithKline.

GSK has been working on the vaccine for some time as part of its bio-security collaboration with federal defense and health officials, according to Donna Altenpohl, vice president for public policy: 254 more words


RT: ‘All hands on deck’: US pushes ahead with Ebola vaccine trials on humans

Published time: August 28, 2014 22:53
Edited time: August 29, 2014 07:03

Reuters / Mariana Bazo

Twenty healthy volunteers will next week enter a 48-week trial for a US-developed vaccine against the deadly Ebola virus. 545 more words


Ebola virus vaccine to be tested in UK #Ebola #EbolaVaccineTrials #GlaxoSmithKline

CHRIS HIGGINS.Scientist takes blood out test tube in laboratory test of Ebola Zaire virus. luchschen / Shutterstock

Human trials of an Ebola vaccine are set to begin in Britain within a few weeks, with the number of potential cases projected to reach 20,000 during this outbreak. 303 more words


Experimental Ebola Vaccine Heads to Human Trials

An experimental Ebola vaccine will soon enter phase one of a clinical trial on humans, the National Institute of Health said Thursday.

Initial testing will take place at the NIH’s Clinical Center in Bethesda, Maryland, while the NIH is in the process of working out tests in Ebola-stricken West Africa. 237 more words

The Price of Painkillers

DISCLAIMER: Since I mention some specific branded pharmaceutical products in this article, I want to make it very clear that I don’t intend to promote any particular product and have no conflict of interests to declare. 1,144 more words

New Zealand

You never know what you can become; harnessing randomness to fuel innovation

What could organizations like GlaxoSmithKline (GSK) and McLaren possibly have in common? A quick look at their core businesses and you would almost instantly think; none. 512 more words

FDA Breakthrough Therapy Designation: GSK Receives Approval For Additional Indication For Promacta

GlaxoSmithKline (GSK) announces on August 26th that the  FDA approves a supplemental New Drug Application (sNDA), for the once-daily use of Promacta (Eltrombopag) in patients with Severe Aplastic Anemia (SAA), who have had an insufficient response to Immunosuppressive Therapy (IST). 184 more words

Orphan Drug Development